Pregnancy and Lupus

Delivered in a case study format, Dr. Rosalind Ramsey-Goldman’s lecture on pregnancy and SLE covers fertility preservation strategies, contraception methods, medication use during pregnancy and lactation, and assessing the effect of pregnancy on maternal disease and fetal outcome.

Expiration Date:
September 15, 2018

Available for CHES/CPH credit until:
September 30, 2016

Course Credits:
1.0 hours

The American College of Rheumatology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The ACR designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity is intended for rheumatologists, internists, emergency medicine physicians, ophthalmologists, OB-GYNs, dermatologists and other health professionals who may treat female patients with or at risk for lupus.

Originally released on April 22, 2011. Reviewed and re-released on September 15, 2015. Expires on September 15, 2018

1.0 hours

Certain ethnic, gender and racial patient populations are prone to a higher incidence and prevalence of lupus and sometimes poorer quality health care than other Americans. The health care system will have to change and adjust, as the nation’ population grows and diversifies, to meet the needs of an increasingly multicultural patient base.

Upon completion of this activity, participants should be able to:

  1. Identify fertility preservation strategies
  2. Discuss contraception methods
  3. Evaluate pregnancy effect on maternal disease and fetal outcome
  4. Describe medication use during pregnancy and lactation

Use of Professional Judgment

This activity, including all educational links, is intended to be used as a tool to assess the base knowledge of the learner. The information presented relates to basic principles of diagnosis and therapy, and is meant in no way to substitute for an individual patient assessment based upon the healthcare provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient.

Drugs and Doses

When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule of contraindications.

ACR Disclosure Statement

The American College of Rheumatology is an independent, professional organization that does not endorse specific procedures or products of any pharmaceutical/biotech concern.


This project was supported by Grant Number 1CPIMP141065-01-00 from the U.S. Department of Health and Human Services office of Minority Health (HHS, OMH).  Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the HHS, OMH.

Pregnancy and SLE Disclosures

View ACR’s ACCME disclosure practices here>

Faculty participating in an ACR-sponsored activity must disclose to the planning committee and audience any financial or other relationship(s) including, but not limited to:

  1. Stock, stock options or bond holdings in a for-profit corporation or self-directed pension plan
  2. Research grants
  3. Employment (full or part-time)
  4. Ownership or partnership
  5. Consulting fees or other remuneration (payment)
  6. Non-remunerative positions of influence such as officer, board member, trustee or public spokesperson
  7. Receipt of royalties
  8. Speakers' bureau
  9. Other

The faculty reported the following disclosures:

Rosalind Ramsey-Goldman, M.D.  Solovy/Arthritis Research Society Research Professor, Rheumatology Division, Feinberg School of Medicine, Northwestern University. Dr. Ramsey-Goldman acknowledges the following relationships:

  • Grant Support
  • National Institutes of Health/NIAMS: K24-AR02318, P60-AR48098, NCRR/GCRC M01-RR00048), T32-AR07611
  • Kirkland Scholars
  • Site Investigator
  • Genelabs, Aspreva, Human Genomes Science, Genentech, Serono, Genentech/Roche, xDx
  • Data Safety Monitoring Board
  • NIH; Bristol Myers Squibb
  • Consultant/Scientific Advisory Board
  • Genentech; Human Genomes Science
  • Division-Support Medical Company: Bristol-Myers Squibb
  • Advisory Board: Centocor Ortho Biotech, Inc., Human Genome Sciences, Inc.
  • Visiting Professor: Medical University of South Carolina
  • Honoraria: American College of Rheumatology
  • Research Funding: National Institutes of Health, Lupus Foundation of America, Inc.
  • Mentoring Award: Kirkland Scholar Program (Hospital for Special Surgery)
  • Unrestricted Educational Grants: Merck, Proctor and Gamble

The Planning Committee Chairs, all planning committee members and/or staff who are in a position to influence content disclosures are as follows:

Greg Dennis, MD (Review Committee).  Pharmaceutical Product Development, Bioprotection Systems Corporation. Dr. Dennis acknowledges the following relationship: Full-time employee, Pharmaceutical Product Development and Consultant, Bioprotection Systems Corporation.

Amanda Sammut, MD (Review Committee).  Assistant Clinical Professor of Medicine, Columbia University, Department of Medicine. Chief of Rheumatology, Harlem Hospital Center. No relevant financial relationship to disclose.

Sam Lim, MD, MPH (Review Committee).  Assistant Professor of Medicine and Epidemiology, Emory University. No relevant financial information to disclose.

Anna Knippel.  Director, Collaborative Initiatives. No relevant financial relationship to disclose.

Sherry Williams, Esq.  Founder and CEO, Hathor Strategic Consulting, Inc. No relevant financial relationship to disclose

Disclosure information is considered accurate at the time of development. As needed, presenters will provide updated disclosure information to learners prior to content presentation.



  • Microsoft Internet Explorer V5.01 and higher
  • Recommendation is Internet Explorer 5.5 and higher

Operating System

  • Windows
  • Macintosh
  • Recommendation is Windows

Internet Connection

  • Broadband connection (DSL, cable or T1) recommended
  • While it is in the best interest of participants to take the exam through a broadband connection (DSL, cable or T1) rather than through a much slower dial-up connection, it is not an absolute requirement. Please realize that a dial-up connection may slow down the examination process.

Screen Resolution

  • 800 x 600 or better
  • 1024 x 768 is preferred

For technical support please complete the ACR online contact form.